Oragenics, Inc. — Q2 2013 Form 10-Q
Business context and reporting period. The company develops antibiotics and oral-health products and sells ProBiora3 probiotic products. This unaudited filing covers the quarter and six months ended June 30, 2013; comparisons are to the corresponding 2012 periods. Oragenics reported 27,514,080 common shares outstanding on August 9, 2013.
Financial results and position
| Metric | Three months ended June 30, 2013 | Three months ended June 30, 2012 | Six months ended June 30, 2013 | Six months ended June 30, 2012 |
|---|---|---|---|---|
| Revenue | $167,668 | $256,407 | $344,075 | $636,934 |
| Gross profit | $81,011 | $144,149 | $193,469 | $326,467 |
| Gross margin | 48.3% | 56.2% | 56.2% | 51.3% |
| Operating expenses | $2,156,279 | $7,012,848 | $4,004,861 | $8,674,040 |
| Net loss | $(2,074,035) | $(6,928,771) | $(3,663,995) | $(8,545,679) |
| Net loss per share | $(0.08) | $(0.52) | $(0.13) | $(0.86) |
- Six-month operating cash use was $3,581,139, versus $2,292,991 in 2012. Investing activities used $6,374; financing activities provided $29,061. Cash declined $3,558,452 to $6,367,515.
- At June 30, cash was $6,367,515, working capital was $5,634,613, total assets were $7,071,389, and total current liabilities were $1,387,916. Accumulated deficit was $57,750,357.
- Current liabilities included $142,306 of short-term notes payable, primarily insurance-premium financing, and $1,222,463 of accounts payable and accrued expenses. The balance sheet shows no long-term debt.
- Inventory was $303,004, net of an approximately $13,000 reserve, down from an approximately $253,000 reserve at year-end. The cash-flow statement reports a $(240,005) adjustment for expired inventory; the filing text does not clearly explain this presentation.
Material changes and notable items
- Revenue fell 35% in Q2 and 46% for the first half. Management attributed the declines mainly to lower private-label sales and grant revenue in Q2, and lower international sales and grant revenue for the first half.
- Reported R&D expense declined sharply year over year because 2012 included a $5,798,001 stock-paid Intrexon technology access fee. Excluding that fee, first-half 2013 R&D expense increased $649,793, principally due to higher Intrexon consulting costs.
- SG&A increased 82% in Q2 and 22% in the first half, reflecting higher marketing and advertising, compensation, stock-based compensation, and filing and registration costs. Gross margin declined in Q2 but improved for the first half.
- First-half other income included $144,503 related to an unrelated third party’s purchase of the company’s membership interest in a mutual insurer. Interest expense was lower than in 2012, following conversion of shareholder debt into common stock.
- April 2013 amendments to University of Florida Research Foundation licenses reduced aggregate minimum annual maintenance payments from $100,000 to $20,000 and removed a $1 million annual R&D spending requirement. Sublicense revenue sharing rose from 20% to 22%, with additional commercialization and royalty payment terms.
Outlook, risks and contingencies
- Management said available cash was expected to fund the business plan through March 2014; the filing also describes cash as sufficient for at least the next nine months. Additional financing is not committed or assured. Without funding, the company may need to curtail development, reduce costs, or forego opportunities, and equity financing could dilute shareholders.
- Management expects continuing losses and negative cash flow, with substantial development and commercialization costs. ProBiora3 sales and marketing are being expanded, but the new marketing plan was still in rollout and Q2 results had not met expectations.
- Management planned MU1140 preclinical work in the second half of 2013 and, if successful, anticipated an FDA Investigational New Drug application by Q1 2015. Commercial availability was not expected before sometime after 2016. Manufacturing capacity, clinical progress, regulatory approvals, and Intrexon collaboration outcomes remain significant uncertainties.
- Baseline data from two ProBiora3 clinical studies did not support enhanced claims; the company decided to terminate those studies and redirect resources to a more standardized study design. A two-year children’s study in Scandinavia continued. The company discontinued pursuit of its SMaRT Phase 1b trial after enrollment difficulties and is exploring partnering opportunities.
- The company depends on key suppliers for probiotic products and faces product shelf-life, inventory, and returns risks. Management reported disclosure controls effective but acknowledged an unremediated material weakness in internal control over financial reporting due to insufficient personnel for segregation of duties.
- The filing reports no material legal proceedings and no defaults upon senior securities.
Important facts for investors to verify
- Whether cash burn, working capital, and fundraising plans support operations beyond the stated March 2014 runway.
- ProBiora3 sales trends and whether increased marketing spending produces sustained revenue growth.
- Progress and cost of MU1140 manufacturing, preclinical testing, and the Intrexon collaboration, including the timing and financing of any clinical program.
- Potential dilution from future financings, warrants, or Intrexon milestone share issuances; no Intrexon milestones had been achieved by June 30, 2013.
- Resolution of the segregation-of-duties material weakness and the reported expired-inventory cash-flow adjustment.